Compare SHAK & ACLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SHAK | ACLX |
|---|---|---|
| Founded | 2004 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.7B |
| IPO Year | 2014 | 2022 |
| Metric | SHAK | ACLX |
|---|---|---|
| Price | $86.60 | $114.35 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 24 | 15 |
| Target Price | $115.45 | ★ $115.85 |
| AVG Volume (30 Days) | 1.3M | ★ 3.6M |
| Earning Date | 05-21-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 354.17 | N/A |
| EPS | ★ 1.09 | N/A |
| Revenue | ★ $1,445,306,000.00 | $22,286,000.00 |
| Revenue This Year | $16.45 | $329.40 |
| Revenue Next Year | $14.85 | $151.37 |
| P/E Ratio | $79.82 | ★ N/A |
| Revenue Growth | ★ 15.38 | N/A |
| 52 Week Low | $72.93 | $47.86 |
| 52 Week High | $142.23 | $114.80 |
| Indicator | SHAK | ACLX |
|---|---|---|
| Relative Strength Index (RSI) | 38.92 | 83.30 |
| Support Level | $86.45 | $66.06 |
| Resistance Level | $89.42 | $114.80 |
| Average True Range (ATR) | 4.68 | 0.35 |
| MACD | -0.95 | -0.30 |
| Stochastic Oscillator | 0.93 | 65.68 |
Shake Shack Inc is a roadside burger stand. It serves a classic American menu of premium burgers, hot dogs, crispy chicken, frozen custard, crinkle-cut fries, shakes, beer, wine and more. The company's burgers are made with a whole-muscle blend of all-natural, hormone and antibiotic-free Angus beef, ground fresh daily, cooked to order, and served on a non-genetically modified organism (GMO) potato bun. Its menu focuses on food and beverages, crafted from a range of classic American foods. The company serves draft Root Beer, seasonal freshly-squeezed lemonade, organic fresh brewed iced tea, cold brew coffee, organic apple juice, and Shack20 bottled water.
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.